AstraZeneca Pharmaceuticals LP

1968 articles with AstraZeneca Pharmaceuticals LP

• Imfinzi (durvalumab) is the First Immunotherapy to Demonstrate Significant Overall Survival Benefits in Unresectable, Stage III Non-Small Cell Lung Cancer

  9/25/2018

  Phase III PACIFIC data presented at the IASLC 2018 World Conference on Lung Cancer in Toronto shows 32 per cent reduced risk of death for patients treated with Imfinzi compared to standard of care

• AstraZeneca Ships FLUMIST® QUADRIVALENT Vaccine in the US for 2018-2019 Flu Season

  9/25/2018

  Appropriate patients can receive the only needle-free, nasal spray flu vaccine from physicians as soon as late September

• 

  Tesaro Highlights Benefits of Maintenance Therapy Zejula During Ovarian Cancer Awareness Month

  9/25/2018

  Ovarian cancer is the fifth leading cause of cancer-related deaths in the United States. It is estimated that this year there will be more than 22,000 women in the U.S. diagnosed with the disease and about 14,000 disease-related deaths.
• 

  AstraZeneca’s Imfinzi Cuts Lung Cancer Death by a Third

  9/25/2018

  AstraZeneca and its MedImmune division released data on overall survival (OS) in its Phase III PACIFIC clinical trial of Imfinzi (durvalumab).
• 

  A Look at 7 Upcoming and Recently Announced Biotech IPOs

  9/24/2018

  According to BioPharm Catalyst there were, or soon will be, 58 biopharma IPOs in 2018. And the trend doesn’t appear to be slowing. Here’s a look at five upcoming biotech IPOs.

• FARXIGA Achieved a Positive Result in the Phase III DECLARE-TIMI 58 Trial, a Large Cardiovascular Outcomes Trial in 17,000 Patients with Type 2 Diabetes

  9/24/2018

  FARXIGA met the primary composite endpoint of a statistically-significant reduction in hospitalization for heart failure or CV death in a broad patient population

• 

  AstraZeneca’s Diabetes Drug Farxiga Decreases Risk of Cardiovascular Disease

  9/24/2018

  AstraZeneca announced positive results from its Phase III DECLARE-TIMI 58 cardiovascular outcomes clinical trial of Farxiga (dapagliflozin).
• 

  Astellas Pushes Outside of Oncology, Releases Positive Results in Anemia Trials

  9/21/2018

  Tokyo-based Astellas Pharma announced that its roxadustat met its primary endpoints in the Phase III ALPS clinical trial in chronic kidney disease (CKD) patients with anemia not on dialysis. The focus of the drug is on anemia.
• 

  Clovis Oncology to Pay the SEC $20 Million for Misleading Investors

  9/19/2018

  Clovis Oncology will pay more than $20 million in penalties to settle charges that Chief Executive Officer Patrick Mahaffy and its former Chief Financial Officer Erle Mast misleading investors about the company’s lung cancer treatment leading up to a public offering of stock.
• 

  AstraZeneca’s Asthma Drug Looks Good in Multiple Late-Stage Trials

  9/19/2018

  AstraZeneca released positive results from the BORA Phase III extension clinical trial of Fasenra (benralizumab) as an add-on maintenance therapy in patients with severe eosinophilic asthma that had already completed either the SIROCCO or CALIMA Phase III trials.
• 

  57% of Americans OK with Genetically Engineering Animals for Organ Transplants

  9/19/2018

  A recent survey by the Pew Research Center found that 57 percent of Americans surveyed thought it was appropriate to use genetically engineered animals to grow organs for human transplants.

• FASENRA (benralizumab) Shows Consistent Safety and Sustained Efficacy in Long-Term Phase III BORA Trial in Severe Eosinophilic Asthma

  9/18/2018

  74% of continuously-treated patients with a blood eosinophil count 300 or greater were exacerbation-free in the second year of treatment

• 

  Novo Nordisk to Lay off 400 to Focus on Innovation

  9/18/2018

  Novo Nordisk is laying off 400 staffers so it can shift funds toward biological and technological innovation.
• 

  AstraZeneca Plans to Seek Regulatory Approval for COPD Drug PT010 Following Phase III Trial

  9/17/2018

  Following a setback in a chronic obstructive pulmonary disease (COPD) clinical trial in August, AstraZeneca unveiled data from a separate trial on Sunday that showed its triple combination therapy PT010 outperformed its dual-therapy rivals eight of nine times.

• Horizon Discovery Edit-R crRNA Libraries Adopted by AstraZeneca as Part of its Functional Genomics Discovery Platform

  9/14/2018

  AstraZeneca joins Horizon’s Genomics Discovery Initiative

• 

  FDA Gives AstraZeneca’s Lumoxiti a Thumbs-up for Hairy Cell Leukemia

  9/14/2018

  AstraZeneca and its research-and-development arm, MedImmune, announced that the U.S. FDA approved Lumoxiti (moxetumomab pasudotox-tdfk) for adults with relapsed or refractory hairy cell leukemia (HCL) who have had at least two previous systemic therapies, including with a purine nucleoside analog.

• US FDA Approves LUMOXITI™ (moxetumomab pasudotox-tdfk) for Certain Patients with Relapsed or Refractory Hairy Cell Leukemia

  9/13/2018

  Approval of LUMOXITI, a first-in-class medicine for hairy cell leukemia, marks first new treatment option for patients in over 20 years

• 

  Movers and Shakers for Sept. 10

  9/10/2018

  Let's take a look at who made a splash in the pharma and biotech world the past week.
• 

  GSK’s Nucala Shows Superior Benefits to Other IL-5 Inhibitors in Asthma, But Fails as a COPD Drug

  9/10/2018

  Days after receiving a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for Nucala (mepolizumab) as an add-on COPD treatment, GlaxoSmithKline released data that showed the same medication was a superior treatment in severe eosinophilic asthma in patients with similar bloo...

• Tezepelumab Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Severe Asthma Without An Eosinophilic Phenotype

  9/7/2018

  Designation Supported by Phase 2b PATHWAY Data That Demonstrated Tezepelumab Significantly Reduced Asthma Exacerbations Compared to Placebo in Severe Asthma Patients